MCID: ESN014
MIFTS: 34

Eosinophilic Enteropathy

Categories: Gastrointestinal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Eosinophilic Enteropathy

MalaCards integrated aliases for Eosinophilic Enteropathy:

Name: Eosinophilic Enteropathy 53 72
Eosinophilic Gastroenteritis 53 72
Eosinophilic Esophagitis 53 72
Eosinophilic Gastritis 53 72
Eosinophilic Gastroenteropathy 53
Eosinophilic Enteritis 53

Classifications:



External Ids:

UMLS 72 C0267154 C0341106 C1262481 more

Summaries for Eosinophilic Enteropathy

NIH Rare Diseases : 53 Eosinophilic enteropathy is a condition that causes a type of white blood cell called an eosinophil to build up in the gastrointestinal system and in the blood. Eosinophils play a role in the body's immune response by releasing toxins. Eosinophils are associated with allergic-type reactions, but their specific function is largely unknown.When eosinophils build up in the gastrointestinal tract, this begins to affect the body by causing polyps, tissue break down, inflammation, and ulcers. Eosinophilic enteropathy can occur in children or adults and is characterized by intolerance to some foods. Eosinophilic enteropathy can affect any part of the gastrointestinal tract, and is often named by the part affected: colon (colitis), esophagus (esophagitis), stomach (gastritis), or both the stomach and small intestine (gastroenteritis).

MalaCards based summary : Eosinophilic Enteropathy, also known as eosinophilic gastroenteritis, is related to esophagitis, eosinophilic, 1 and eosinophilic gastritis, and has symptoms including vomiting and epigastric pain. The drugs Fluticasone and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include small intestine, colon and testes.

Related Diseases for Eosinophilic Enteropathy

Diseases related to Eosinophilic Enteropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 esophagitis, eosinophilic, 1 12.7
2 eosinophilic gastritis 11.8
3 esophagitis 11.4
4 eosinophilic gastroenteritis 11.4
5 autosomal dominant intellectual disability 30 11.3
6 dysphagia 11.1
7 hypereosinophilic syndrome 11.0
8 gastroesophageal reflux 11.0
9 food allergy 10.8
10 ige responsiveness, atopic 10.7
11 esophageal disease 10.6
12 proton-pump inhibitor-responsive esophageal eosinophilia 10.6
13 rhinitis 10.6
14 allergic rhinitis 10.6
15 dermatitis, atopic 10.5
16 peptic esophagitis 10.5
17 gastroenteritis 10.5
18 celiac disease 1 10.5
19 intestinal obstruction 10.5
20 barrett esophagus 10.4
21 dermatitis 10.4
22 candidiasis 10.4
23 pancreatitis 10.4
24 achalasia 10.4
25 allergic hypersensitivity disease 10.4
26 gastrointestinal system disease 10.4
27 hypereosinophilic syndrome, idiopathic 10.3
28 duodenal ulcer 10.3
29 iron metabolism disease 10.3
30 esophageal candidiasis 10.3
31 acute pancreatitis 10.3
32 vasculitis 10.3
33 tracheoesophageal fistula with or without esophageal atresia 10.3
34 esophageal atresia 10.3
35 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.3
36 inflammatory bowel disease 10.2
37 dyspepsia 10.2
38 deficiency anemia 10.2
39 iron deficiency anemia 10.2
40 intestinal perforation 10.2
41 churg-strauss syndrome 10.2
42 duodenal obstruction 10.2
43 allergic angiitis 10.2
44 eosinophilic granulomatosis with polyangiitis 10.2
45 fibrosis of extraocular muscles, congenital, 1 10.2
46 mastocytosis 10.2
47 gastritis 10.2
48 myositis 10.2
49 urticaria 10.2
50 herpes simplex 10.2

Graphical network of the top 20 diseases related to Eosinophilic Enteropathy:



Diseases related to Eosinophilic Enteropathy

Symptoms & Phenotypes for Eosinophilic Enteropathy

UMLS symptoms related to Eosinophilic Enteropathy:


vomiting, epigastric pain

Drugs & Therapeutics for Eosinophilic Enteropathy

Drugs for Eosinophilic Enteropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Citalopram Approved Phase 4 59729-33-8 2771
4 Soy Bean Phase 4
5 Cromolyn Sodium Phase 4
6 Olive Phase 4
7 Respiratory System Agents Phase 4
8 Anti-Asthmatic Agents Phase 4
9 Gastrointestinal Agents Phase 4
10 Antacids Phase 4
11 Anti-Ulcer Agents Phase 4
12 Bronchodilator Agents Phase 4
13 Anti-Inflammatory Agents Phase 4
14 Anti-Allergic Agents Phase 4
15 Dermatologic Agents Phase 4
16 Proton Pump Inhibitors Phase 4
17 Neurotransmitter Agents Phase 4
18 Autonomic Agents Phase 4
19 Peripheral Nervous System Agents Phase 4
20 Cholinergic Agents Phase 4
21 Serotonin Agents Phase 4
22 Psychotropic Drugs Phase 4
23 Serotonin Uptake Inhibitors Phase 4
24 Parasympatholytics Phase 4
25 Antidepressive Agents Phase 4
26 Antidepressive Agents, Second-Generation Phase 4
27 Neurotransmitter Uptake Inhibitors Phase 4
28 Muscarinic Antagonists Phase 4
29 Cholinergic Antagonists Phase 4
30 Antiparkinson Agents Phase 4
31
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
32 Reslizumab Approved, Investigational Phase 2, Phase 3
33
Esomeprazole Approved, Investigational Phase 2, Phase 3 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
34
Histamine Approved, Investigational Phase 3 51-45-6 774
35
Ketotifen Approved Phase 3 34580-13-7, 34580-14-8 3827
36 Antibodies Phase 3
37 Immunoglobulins Phase 3
38 Antibodies, Monoclonal Phase 3
39 Immunologic Factors Phase 3
40 Antipruritics Phase 3
41 Histamine Antagonists Phase 3
42 Histamine H1 Antagonists Phase 3
43
Histamine Phosphate Phase 3 51-74-1 65513
44
Omalizumab Approved, Investigational Phase 2 242138-07-4
45
Infliximab Approved Phase 2 170277-31-3
46 Benralizumab Approved, Investigational Phase 1, Phase 2 1044511-01-4
47
Budesonide Approved Phase 2 51333-22-3 63006 5281004
48
tannic acid Approved Phase 2 1401-55-4
49
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
50
Losartan Approved Phase 2 114798-26-4 3961

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
3 COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
4 Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
5 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
6 Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP) Terminated NCT02825342 Phase 4 Citalopram
7 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
8 Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial Completed NCT00266578 Phase 3 Fluticasone Propionate
9 An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
10 Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
11 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study Completed NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
12 An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 Completed NCT00635089 Phase 3 reslizumab
13 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
14 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
15 A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
16 A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
17 Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial Recruiting NCT02778867 Phase 2, Phase 3 Flovent
18 Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
19 Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis Active, not recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
20 A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
21 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Completed NCT03496571 Phase 2 AK002
22 A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
23 Pilot Study of Omalizumab in Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
24 A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
25 A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE) Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
26 A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
27 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
28 Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents Completed NCT00762073 Phase 2 budesonide;placebo
29 A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children Completed NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
30 A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) Completed NCT00358449 Phase 2 mepolizumab
31 Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
32 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
33 A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02379052 Phase 2 Dupilumab;Placebo
34 Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study Completed NCT00271349 Phase 2 Budesonide
35 A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE) Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
36 A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
37 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
38 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
39 Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
40 A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
41 A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary Evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous Anti-human Interleukin-5 (Mepolizumab, 750mg and 1500mg) in the Treatment of Eosinophilic Oesophagitis in Adults Completed NCT00274703 Phase 2 mepolizumab
42 Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
43 A Pilot Phase II Study of the Efficacy of Humanized Anti-IL5 Antibody (SCH55700) in Reducing Eosinophilia in Patients With Hypereosinophilic Syndrome or Eosinophilic Gastroenteritis Refractory to or Intolerant of Conventional Therapy Completed NCT00017862 Phase 2 SCH55700
44 A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
45 A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms Recruiting NCT03656380 Phase 2 Mepolizumab 300 mg;Mepolizumab 100 mg
46 Prospective Evaluation of the Clinical Utility of Budesonide for the Prevention of Esophageal Strictures After Endotherapy Recruiting NCT02069847 Phase 2 Budesonide
47 A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder Active, not recruiting NCT03029091 Phase 2 Losartan Potassium
48 A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
49 FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis Active, not recruiting NCT03191864 Phase 2 APT-1011;Placebo
50 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Active, not recruiting NCT01821898 Phase 2 Oral Budesonide

Search NIH Clinical Center for Eosinophilic Enteropathy

Genetic Tests for Eosinophilic Enteropathy

Anatomical Context for Eosinophilic Enteropathy

MalaCards organs/tissues related to Eosinophilic Enteropathy:

41
Small Intestine, Colon, Testes, Bone, Liver, T Cells, Bone Marrow

Publications for Eosinophilic Enteropathy

Articles related to Eosinophilic Enteropathy:

(show top 50) (show all 819)
# Title Authors PMID Year
1
Myenteric networks of interstitial cells of Cajal are reduced in horses with inflammatory bowel disease. 38
31397916 2019
2
Endoscopic Features and Diagnostic Procedures of Eosinophilic Gastroenteritis. 38
30996166 2019
3
Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. 38
30982212 2019
4
Modified oral enteric-coated budesonide regimens to treat pediatric eosinophilic gastroenteritis, a single center experience. 38
30763733 2019
5
Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. 38
31342146 2019
6
Causes of eosinophilic ascites - A systematic review. 38
30864403 2019
7
Appearance of Gastric Polypoid Lesions in Eosinophilic Gastroenteritis. 38
31232829 2019
8
Retrospective study of budesonide in children with eosinophilic gastroenteritis. 38
31141816 2019
9
Eosinophilic pancreatitis versus pancreatitis associated with eosinophilic gastroenteritis -a systematic review regarding clinical features and diagnosis. 38
31120859 2019
10
Abdominal ascites in children as the presentation of eosinophilic gastroenteritis: A surgeon's perspective. 38
30528318 2019
11
Eosinophilic gastrointestinal diseases - Pathogenesis, diagnosis, and treatment. 38
31000445 2019
12
Eosinophilic Gastrointestinal Disorders. 38
30903439 2019
13
Eosinophilic Gastroenteritis Presenting With Gastric Perforation. 38
29366927 2019
14
Clinical and pathological profile of eosinophilic gastroenteritis. 38
30113369 2019
15
Abnormal thymic stromal lymphopoietin expression in the gastrointestinal mucosa of patients with eosinophilic gastroenteritis. 38
30763528 2019
16
A Case of Eosinophilic Gastroenteritis Associated with Eosinophilic Ascites Diagnosed by Full-Thickness Biopsy of the Small Intestine. 38
30755542 2019
17
Efficacy of an elimination diet in a patient with eosinophilic gastroenteritis : a pediatric case with multiple food allergies. 38
31064942 2019
18
Clinical features and treatment outcomes of eosinophilic gastroenteritis : an analysis of 28 cases. 38
30888747 2019
19
Eosinophilic gastroenteritis: diagnosis and clinical perspectives. 38
31239747 2019
20
Eosinophilic gastroenteritis: An unusual presentation of a rare disease. 38
29555104 2019
21
[Refractory eosinophilic gastroenteritis with gastritis, duodenal ulcer, and colitis: a case report]. 38
31406072 2019
22
Predictable and Unusual Adverse Effects of Immunosuppression in Pediatric Liver Transplant Patients. 38
30777562 2019
23
Eosinophilic gastroenteritis: Atypical cause for chronic diarrhea in human immunodeficiency virus-associated immunosuppression. 38
31143864 2019
24
Impaired Health-Related Quality of Life in Adolescent Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Impact of Core Symptoms. 38
30828572 2019
25
Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis. 38
29596982 2018
26
Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab. 38
30056148 2018
27
Can Eosinophilic Esophagitis Cause Achalasia and Other Esophageal Motility Disorders? 38
30315308 2018
28
Eosinophilic gastroenteritis complicating acute calculus eosinophilic cholecystitis 6 months after cholecystectomy. 38
30370999 2018
29
Eosinophilic Colitis Associated with Emtricitabine/Tenofovir. 38
30648039 2018
30
Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. 38
29940308 2018
31
Hypereosinophilia and epigastralgia after visiting Tunisia: a rare differential diagnosis of helminthiases. 38
30270843 2018
32
Nationwide questionnaire-based survey of oral immunotherapy in Japan. 38
29571889 2018
33
Diagnosis, Natural History and Treatment of Eosinophilic Enteritis: a Review. 38
29968127 2018
34
Eosinophilic Gastroenteritis and Colitis: Not Yet Ready for the Big Leagues. 38
29620603 2018
35
Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. 38
29434146 2018
36
[Clinical analysis of eosinophilic gastroenteritis in 71 children]. 38
29996182 2018
37
Massive hemorrhagic ascites: A rare presentation of eosinophilic gastroenteritis. 38
30079343 2018
38
[Hematemesis as debut of eosinophilic gastroenteritis in infants]. 38
29037954 2018
39
A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms. 38
29212311 2018
40
Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment. 38
29476289 2018
41
Quantification of the duodenal eosinophil content in adults: a necessary step for an evidence-based diagnosis of duodenal eosinophilia. 38
29488232 2018
42
Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. 38
29533199 2018
43
Intestinal overexpression of interleukin (IL)-15 promotes tissue eosinophilia and goblet cell hyperplasia. 38
29363170 2018
44
Eosinophil Counts in Mucosal Biopsies of the Ileum and Colon: Interobserver Variance Affects Diagnostic Accuracy. 38
30519390 2018
45
Classification of eosinophilic disorders of the small and large intestine. 38
29127496 2018
46
[A retrospective study of the clinical characteristics and treatment of 93 adult patients with eosinophilic gastroenteritis]. 38
30197393 2018
47
Takayasu's arteritis associated with eosinophilic gastroenteritis, possibly via the overactivation of Th17. 38
29942355 2018
48
Ascites in a Young Woman: A Rare Presentation of Eosinophilic Gastroenteritis. 38
29862093 2018
49
Post-partum eosinophilic gastroenteritis: A case report. 38
28081983 2018
50
[Recent progress in the research of Eosinophilic GastroIntestinal Diseases (EGIDs)]. 38
30298838 2018

Variations for Eosinophilic Enteropathy

Expression for Eosinophilic Enteropathy

Search GEO for disease gene expression data for Eosinophilic Enteropathy.

Pathways for Eosinophilic Enteropathy

GO Terms for Eosinophilic Enteropathy

Sources for Eosinophilic Enteropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....